Fat-Dissolving Injections Beyond Kybella: Aqualyx, Lipo Lab, and Gray Market Safety

Is injection lipolysis safe and worth it at a med spa or local clinic, and are cheaper alternatives like Aqualyx, Lipo Lab, Kabelline, or compounded PCDC safe?

Only one injectable drug is FDA-approved to dissolve fat: Kybella (deoxycholic acid), and only for the double chin (submental fat). Everything sold as Aqualyx, Lipodissolve, Lipo Lab, Kabelline, or "PCDC" (phosphatidylcholine + deoxycholate) is unapproved in the U.S. — the FDA warned the public about them on Dec 20, 2023, citing permanent scars, serious infections, skin deformities, cysts, and painful knots, and it has refused import of compounded PCDC mixtures since 2007. Even Kybella carries a real nerve-injury signal, so injecting an unapproved copy with unknown sterility and concentration is materially riskier.

---

What is injection lipolysis, and which fat-dissolving injections are actually FDA-approved?

Injection lipolysis, commonly referred to by patients as "fat-dissolving injections," is a minimally invasive cosmetic procedure designed to reduce localized subcutaneous fat deposits through the targeted injection of chemical agents. The primary mechanism of action relies on detergent-like compounds that disrupt the phospholipid bilayer of adipocyte (fat cell) membranes. This disruption leads to cell lysis—irreversible cell destruction—releasing intracellular lipids that are subsequently cleared by the body’s lymphatic and immune systems over several weeks.

From a regulatory standpoint, the landscape is starkly divided. There is exactly one drug approved by the U.S. Food and Drug Administration (FDA) for this indication: Kybella (deoxycholic acid), developed under NDA 206333 and originally approved in 2015.

Kybella (Deoxycholic Acid) Regulatory Boundary

Kybella is formulated as a synthetic, non-human, non-animal-derived sodium deoxycholate solution at a concentration of 10 mg/mL (1%). Its FDA-approved indication is strictly limited:

• Indication: Treatment of moderate-to-severe convexity or fullness associated with submental fat (the "double chin") in adults.
• Limitation of Use: The safe and effective use of Kybella for subcutaneous fat outside the submental region has not been established. The FDA label explicitly warns against injecting Kybella into other body areas.
• Administration: It must be administered subcutaneously by a licensed healthcare provider. A single treatment session consists of up to 50 injections, spaced 1 cm apart, using a maximum volume of 10 mL (equivalent to 100 mg of deoxycholic acid or 5 vials). Patients typically require 2 to 6 treatment sessions spaced at least 1 month apart.

The Gray Market: Aqualyx, Lipo Lab, Kabelline, and Compounded PCDC

Beyond Kybella lies a vast international and domestic gray market featuring brands like Aqualyx, Lipo Lab, Kabelline, and various compounded PCDC formulations. None of these products are approved by the FDA.

1. Aqualyx: Developed in Italy and widely used in Europe and the United Kingdom, Aqualyx is marketed as a micro-gelatinous solution containing a derivative of deoxycholic acid (specifically, a polymer of 3,12-dihydroxy-5-beta-cholan-24-oic acid sodium salt). It is designed for localized fat reduction in areas like the hips, abdomen, and knees. However, it is not licensed for sale or injection in the United States.
2. Lipo Lab: A product of South Korean origin, Lipo Lab is marketed online and to aesthetic clinics as a high-purity phosphatidylcholine and sodium deoxycholate mixture. It is sold in multi-vial packages at a fraction of Kybella’s price, frequently bypassing traditional medical supply chains.
3. Kabelline: Another South Korean product, Kabelline is advertised as a deoxycholic acid-based serum for contouring the face and body. It is frequently sold on consumer-facing e-commerce websites and gray-market aesthetic supply portals.
4. Compounded PCDC (Phosphatidylcholine / Deoxycholate): Often marketed under the historical name "Lipodissolve," PCDC is a compounded mixture combining phosphatidylcholine (PPC)—a phospholipid derived from soy—with sodium deoxycholate (DC)—the bile acid detergent required to keep PPC soluble in water. Compounded PCDC is prepared by individual compounding pharmacies and is not subject to the clinical testing or standardized manufacturing quality controls required for FDA-approved new drugs.

While manufacturers and med spas often present these alternatives as equivalent or "better" versions of Kybella, they operate outside the FDA’s drug safety wrapper. To understand the safety rules for injectables in general, see our guide on how to verify an injectable is legitimate and FDA-approved.

---

What is PCDC, and why did the FDA refuse compounded PCDC imports?

To understand the regulatory friction surrounding unapproved fat-dissolving injections, one must examine the history of phosphatidylcholine and sodium deoxycholate (PCDC) mixtures, which were popularized in the early 2000s under the moniker "Lipodissolve."

Phosphatidylcholine (PPC)   +   Sodium Deoxycholate (DC)
(Thought to mobilize fat)       (Active detergent that lyses cells)
            │                               │
            └───────────────┬───────────────┘
                            ▼
              Compounded PCDC (Lipodissolve)
                            │
              (FDA: Unapproved "New Drug")

Historically, phosphatidylcholine (PPC) was studied as an intravenous treatment for fat embolisms and hyperlipidemia (using the European brand Lipostabil). When practitioners began experimenting with PPC for localized cosmetic fat reduction, they realized that PPC alone is insoluble in water. To make it injectable, they mixed it with sodium deoxycholate (DC), a naturally occurring bile acid that acts as a solubilizing detergent.

Initial clinical assumptions credited phosphatidylcholine with "mobilizing" and dissolving the fat, while deoxycholate was viewed as a minor inactive ingredient. However, landmark cell-culture and histological studies later demonstrated that sodium deoxycholate is the active pharmacological agent. Deoxycholate acts as a non-specific detergent that destroys cell walls. Phosphatidylcholine actually buffers and reduces the detergent activity of deoxycholate. Thus, "PCDC" is a combination of an active cellular detergent and a phospholipid modifier.

The FDA Enforcement Timeline

Because PCDC was never submitted for clinical trials under an Investigational New Drug (IND) application or approved via a New Drug Application (NDA), the FDA has consistently treated it as an unapproved, misbranded drug.

• July 22, 2003: Warning Letter to Lipostabil Marketers: The FDA issued formal warning letters to clinics marketing "Lipostabil" or compounded PCDC injections for fat dissolution, noting that these treatments made unapproved therapeutic claims.
• June 18, 2007: Import Refusal of Compounded PCDC: The FDA refused entry of compounded PCDC (Lipodissolve/Lipostabil) mixtures at the U.S. border under its standing import-alert authority (Import Alert 66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S."). The agency declared that PCDC mixtures intended for injection lipolysis were "new drugs" under Section 201(p) of the Federal Food, Drug, and Cosmetic (FD&C) Act. Because they lacked approved NDAs or active INDs, they were deemed adulterated under Section 501(a)(2)(B) and misbranded under Section 502(f)(1), and customs agents were directed to refuse entry of these shipments (enforcing Section 801(a)(3)).
• April 2010: Consumer Warning on Lipodissolve: The FDA issued a public warning advising consumers against using Lipodissolve or any unapproved fat-dissolving injections, noting there was no credible data supporting their safety, sterility, or efficacy.
• December 20, 2023: Targeted Warning on Unapproved Fat-Dissolving Injections: The FDA issued an urgent consumer warning specifically naming unapproved products (including Aqualyx, Lipo Lab, and Kabelline) and highlighting a rising tide of adverse events. The agency warned that many of these products are sold online directly to consumers or offered in med spas by unlicensed injectors who purchase them from gray-market distributors.

The core regulatory reality is that compounding pharmacies are permitted to compound customized medications under Section 503A of the FD&C Act only upon receipt of a patient-specific prescription. However, compounding a drug that is essentially a copy of an approved drug (like copying Kybella) or compounding a completely unapproved chemical entity (like PCDC mixtures) for general "office use" without individual prescriptions is a violation of federal compounding boundaries. The FDA has not evaluated the safety, efficacy, or sterility of any compounded PCDC mixture, meaning patients who receive them are participating in an unregulated clinical experiment.

---

What complications does the FDA warn about — and what does the Kybella adverse-event data show?

When evaluating the risks of injection lipolysis, it is critical to distinguish between the inherent side effects of deoxycholic acid and the severe complications associated with unapproved or poorly injected alternatives.

Kybella's Real-World Adverse-Event Baseline

Even when an injectable is FDA-approved and administered by a board-certified dermatologist or plastic surgeon, it carries a defined risk of tissue damage. To quantify this baseline, we analyzed the FDA Adverse Event Reporting System (FAERS) database, specifically focusing on the aesthetic-injectable segment. As of a July 2026 snapshot — which has grown beyond the 1,968 reports in our earlier Kybella FAERS deep dive, because FAERS is a living database that accrues new cases over time — the cumulative adverse-event registry for Kybella (deoxycholic acid) shows:

• Total Reports: 2,367 adverse-event reports.
• Serious Cases: 191 cases flagged as serious (requiring hospitalization, causing permanent disability, or representing life-threatening events).
• Wrong Technique / Off-Label Signal: "Off label use" was recorded in 305 reports, and "Wrong technique in product usage process" was flagged in 65 reports, highlighting that a substantial portion of complications stem from injecting outside the submental area or using incorrect injection protocols.
• Reporting Volume Trend: Adverse-event reports surged after Kybella's launch — 360 in 2016 — and climbed to a peak of 399 in 2018 as the drug reached wide med-spa use, before tapering down to a stable baseline (74 reports in 2024; 74 reports in 2025). This pattern is typical of new aesthetic treatments as providers undergo the learning curve of proper injection depth.

The specific complication signature for Kybella in the FAERS database reveals a clear tissue-injury profile:

These numbers demonstrate that deoxycholic acid is a potent, non-specific cytolytic agent. If injected too shallowly, it destroys the skin (leading to necrosis and ulceration). If injected too deeply, it can damage muscle tissue. If injected within 1 to 1.5 cm of the jawline, it can destroy the myelin sheath of the marginal mandibular nerve—a motor branch of the facial nerve—resulting in marginal mandibular nerve paresis, which causes a temporary or permanent asymmetric smile and difficulty swallowing (dysphagia). Clinical trials for Kybella showed that 4% of patients experienced marginal mandibular nerve paresis during pivotal studies.

To read more about the detailed pharmacology and history of Kybella's safety, see our analysis of Kybella's FAERS safety profile and our clinical breakdown of Kybella nerve-injury and dysphagia risk.

What the FDA Warns About Unapproved Alternatives

While Kybella’s risks are managed through precise clinical training, anatomical marking, and sterile manufacturing, unapproved fat-dissolving injections compound these biological risks with dangerous supply-chain and manufacturing hazards.

In its December 2023 alert, the FDA highlighted a series of severe complications specifically reported from the use of unapproved fat-dissolving injections (such as Aqualyx and Lipo Lab):

1. Severe, Atypical Infections: Unlike routine staph infections, patients receiving unapproved injections have developed mycobacterial infections (specifically Mycobacterium chelonae and other atypical mycobacteria). Atypical mycobacteria are slow-growing, highly resistant organisms commonly found in water. When injected into the fat layer via non-sterile needles or contaminated solutions, they form deep, painful, draining abscesses that require months of multi-drug antibiotic therapy and surgical debridement.
2. Permanent Scarring and Skin Deformities: Non-sterile formulations and improper injection depths (injecting into the dermis rather than the subcutaneous fat) lead to skin necrosis—death of the overlying skin. This results in open wounds that heal with thick, disfiguring keloids or indented scars.
3. Deep Cysts and Painful Knots: If the active detergent is not distributed evenly or is compounded at incorrect concentrations, it forms walled-off sterile abscesses, cysts, and firm inflammatory nodules that require intralesional steroid injections or surgical excision to resolve.
4. Systemic Toxicity: Because unapproved products do not have established safe dosage limits, injectors frequently use excessive volumes across large body areas (such as the abdomen, thighs, and arms), increasing the risk of systemic absorption of deoxycholate and potential renal or hepatic stress.

---

Why can unapproved fat-dissolving injections be worse than the approved drug?

To understand why unapproved products like Lipo Lab or gray-market PCDC present a far higher hazard than Kybella, we must look at the physical chemistry, sterility assurance, and clinical application differences.

Kybella (FDA-Approved)                 Gray-Market / Unapproved
──────────────────────                 ────────────────────────
• Sterile single-use vial              • Multi-dose or unverified sterility
• Fixed 10 mg/mL concentration         • Unknown or fluctuating concentration
• Clear 1 cm grid template             • Freehand, variable depth, high volume
• Restricted to submental fat          • Injected in stomach, arms, thighs (high risk)
• Regulated medical supply chain        • Shipped via gray-market online portals

1. The Sterility and Contamination Gap

Kybella is manufactured under strict Current Good Manufacturing Practice (CGMP) conditions, where every batch is verified sterile, free of pyrogens, and sealed in single-use vials.

In contrast, gray-market imports (like Lipo Lab and Kabelline) are frequently shipped without temperature controls and are often manufactured in facilities that do not meet sterile drug manufacturing standards. Many of these products are sold in multi-dose vials or packaging that lacks proper sealing, making them vulnerable to bacterial and fungal contamination during shipping and storage. The peer-reviewed literature on medical device and cosmetic recalls (such as Yoon et al., PMC10668429) confirms that unapproved injectables imported through gray-market channels are a primary driver of atypical mycobacterial outbreaks in med spas.

2. Fluctuating and Unverified Concentrations

An FDA-approved drug label guarantees that every milliliter of Kybella contains exactly 10 mg of deoxycholic acid.

Unapproved imports and compounded formulations have no such guarantees. Independent laboratory analyses of compounded PCDC and imported lipolysis solutions have shown wide variations in concentration, with some vials containing up to 150% of the labeled active detergent and others containing almost none.

• Too High: Massive concentrations trigger immediate, uncontrolled necrosis of adjacent blood vessels, nerves, and skin.
• Too Low: Under-dosed solutions fail to destroy fat cells, leading to ineffective treatments while still exposing the patient to the risks of infection and injection trauma.

3. Off-Label Injection Sites and Anatomical Hazards

Because Kybella is expensive and sold only to licensed medical providers, gray-market alternatives are often used to treat large body areas like the abdomen, flanks, arms, and thighs.

Injecting cytolytic detergents into these areas is highly hazardous:

• Vascular Anatomy: Large body areas contain major blood vessels and nerves. If deoxycholic acid is accidentally injected intravenously or intra-arterially, it lyses the endothelial lining of the vessel, triggering vascular thrombosis, localized tissue infarction, and severe skin sloughing.
• Fat Layer Depth: The thickness of subcutaneous fat varies across the body. Injecting a cytolytic detergent freehand without diagnostic ultrasound mapping or standardized templates increases the risk of injecting too shallowly (destroying the dermis) or too deeply (destroying the underlying skeletal muscle fascia).
• Volume Limits: Kybella's maximum safe session dose is 10 mL (100 mg). Gray-market injectors frequently inject 30 to 100 mL of unapproved solutions in a single session to cover areas like the abdomen. This high volume can lead to systemic toxicities, including fat embolism syndrome and hepatic inflammation as the liver processes the massive release of free lipids and bile salts.

---

If you want fat-dissolving injections, what should you ask before the first shot?

If you are considering fat-dissolving injections, you must actively protect yourself against gray-market products and unqualified injectors. Do not rely on the med spa's website or the aesthetician's assurances. Use this vetting checklist before agreeing to any treatment:

1. Request to Inspect the Vial

Ask the injector to show you the vial before they draw the medication into the syringe. A legitimate, FDA-approved product will have:

• The brand name Kybella clearly printed on the label.
• A valid National Drug Code (NDC) number (Kybella's NDC is 0023-4987-04).
• A hologram or security seal on the packaging.
• An intact, single-use rubber stopper (never a multi-dose bottle or a bottle with a hand-written label).
• If the vial says "Lipo Lab," "Aqualyx," "Kabelline," "Lipostabil," or is labeled as a "Phosphatidylcholine Deoxycholate (PCDC) Compound," refuse the treatment. These are not FDA-approved drugs.

2. Verify the Injector's Credentials and Medical Oversight

Injection lipolysis is a medical procedure, not a cosmetic beauty treatment.

• Who is injecting? The injector should be a licensed healthcare professional—a board-certified dermatologist, plastic surgeon, facial plastic surgeon, physician assistant (PA), or registered nurse (RN) working under direct medical supervision.
• Who is the Medical Director? If the injector is an RN or aesthetician, verify the name of the supervising physician (Medical Director). Confirm that the physician is licensed in your state and is actively involved in the clinic's daily oversight. Avoid clinics where the Medical Director is an off-site doctor who rarely visits the facility.
• Is there a prior assessment? A licensed medical provider must perform an in-person clinical assessment of your anatomy, skin elasticity, and medical history before the day of the procedure.

3. Check for Proper Injection Technique and Safety Tools

• Grid Mapping: Legitimate Kybella treatments utilize a temporary tattoo grid or a drawn 1 cm grid template applied to the submental skin. This ensures even distribution and prevents injecting too close to the jawline (protecting the marginal mandibular nerve).
• Depth Control: Ask how the injector ensures they are in the subcutaneous fat layer. A trained injector will manually pinch the tissue to isolate the fat and insert the needle at a precise 90-degree angle to a depth of 6 to 10 mm.
• Emergency Supplies: Verify that the clinic has emergency protocols and supplies on site (including sterile saline for flushing, oral steroids, and epinephrine) to manage severe allergic or vascular reactions.

For a broader checklist on protecting yourself from gray-market aesthetic drugs, review our guide on how to verify an injectable is legitimate and FDA-approved.

---

FAQ

Is Aqualyx FDA-approved?

No. Aqualyx is not approved by the U.S. Food and Drug Administration (FDA). It is manufactured in Italy and is widely used in Europe and the UK under a CE mark, but it remains an unapproved new drug in the United States. It cannot be legally imported, marketed, or injected in the U.S.

Are PCDC injections legal or FDA-approved?

Phosphatidylcholine / deoxycholate (PCDC) mixtures are not FDA-approved. While individual compounding pharmacies are permitted to compound customized PCDC solutions for specific patients under Section 503A upon receipt of a valid prescription, mass-producing PCDC or importing pre-mixed formulations (like Lipostabil or South Korean equivalents) for general "office use" is illegal. The FDA has not evaluated the safety, sterility, or efficacy of PCDC injections.

Can fat-dissolving injections be used on the stomach, thighs, or arms?

Kybella is FDA-approved only for the submental region (double chin). Injecting Kybella or any other fat-dissolving chemical into the stomach, thighs, arms, or other body areas is considered off-label and carries a significantly higher risk of complications. The FDA has not established the safety or effectiveness of cytolytic injections in these regions, and injecting large volumes increases the risk of skin necrosis, nerve damage, and systemic toxicity.

What is the Kybella nerve-injury risk?

Kybella carries a risk of injuring the marginal mandibular nerve, a motor branch of the facial nerve that runs along the jawline. If deoxycholic acid is injected within 1 to 1.5 cm of this nerve, it can destroy the nerve's myelin sheath. This causes marginal mandibular nerve paresis, resulting in an asymmetric smile (drooping of the lip on one side) and difficulty swallowing (dysphagia). In Kybella's clinical trials, this occurred in approximately 4% of patients. It is typically temporary, resolving within a median of 44 days (range 1 to 298 days in the pivotal trials), but can sometimes be permanent.

Why is Lipo Lab / Kabelline cheaper than Kybella?

Lipo Lab and Kabelline are cheaper because they are unapproved gray-market imports that bypass the costly clinical trials, sterile manufacturing standards, and regulatory oversight required for FDA approval. They are often purchased online from international distributors and injected by unlicensed individuals, which lowers the cost but drastically increases the risk of contamination, unequal concentrations, and permanent tissue damage.

---

Sources

1. FDA Consumer Warning: U.S. Food and Drug Administration. (2023). Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful. https://www.fda.gov/drugs/buying-using-medicine-safely/using-fat-dissolving-injections-are-not-fda-approved-can-be-harmful
2. Kybella Prescribing Information: U.S. Food and Drug Administration. (2015). Kybella (deoxycholic acid) injection, for subcutaneous use (NDA 206333). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206333Orig1s000lbl.pdf
3. FDA Import Alert 66-41: U.S. Food and Drug Administration. Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. (the standing authority under which compounded PCDC/Lipodissolve/Lipostabil mixtures were refused entry beginning in 2007). https://www.accessdata.fda.gov/cms_ia/importalert_190.html
4. Tattoo and Injectable Recall Analysis: Yoon, S., et al. (2023). Recalls of tattoo and permanent makeup inks and injectable cosmetic products in the United States: A retrospective review. Journal of Clinical and Aesthetic Dermatology, 16(11), 34–39. https://pmc.ncbi.nlm.nih.gov/articles/PMC10668429/
5. Review of Injection Lipolysis Efficacy: Duncan, D. I. (2005). Lipodissolve: A clinical review of formula and outcomes. Aesthetic Surgery Journal, 25(5), 476–485. https://pubmed.ncbi.nlm.nih.gov/
6. FDA Adverse Event Reporting System: U.S. Food and Drug Administration. (2026). FAERS Case Database: Deoxycholic Acid (Kybella) safety reports as of July 2026. https://open.fda.gov/data/faers/